Jcog9708
Web9 giu 2024 · Objective: The study objective was to evaluate the efficacy and toxicity of chemoradiotherapy with 5-fluorouracil (5-FU) plus cisplatin in patients with Stage I … Web4 giu 2013 · A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, Ando N, Tanaka O, Shinoda M, Yamana H, Ishikura S. Jpn J Clin Oncol, (10):638-643 2009 MED: 19549720
Jcog9708
Did you know?
Web8 dic 2024 · According to the JCOG9708 study, half of patients experienced recurrence and 16 of the 36 with recurrent disease had lesions which could be removed by endoscopy. 5 … Web1 feb 2024 · The JCOG9708 trial, a phase II study of definitive CRT for clinical stage I SCC, revealed 2-and 5-year overall survival rates of 93% and 76%, respectively, which are comparable to those of ...
WebA Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708) WebA Japanese clinical trial (JCOG9708) found that patients with T1 esophageal squamous cell carcinoma (ESCC) who underwent definitive chemoradiotherapy would have a …
Chemoradiotherapy (CRT) was introduced in Japan in the early 1990s as a treatment for potentially unresectable locally advanced esophageal squamous cell carcinoma (ESCC). In a phase II trial, 18 of 54 (33%) patients with clinical T4 and/or M1 lymph node ESCC, who received cisplatin (CDDP)/5 … Visualizza altro CRT has been clinically indicated for patients with resectable ESCC who refuse surgical resection (Table 1). In a retrospective … Visualizza altro Epidermal growth factor receptor (EGFR) is one of the therapeutic targets of ESCC. High levels of EGFR protein expression have been detected in 50–70% of ESCC cases via immunohistochemical analysis, and gene … Visualizza altro For patients with local but unresectable lesions, CRT is the only treatment with a potentially curative intent (Table 2). In a single … Visualizza altro In a retrospective study, extended radiation for regional lymph nodes improved survival compared with a normal radiation field … Visualizza altro Web23 ott 2009 · Read "A Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708), …
Web食道癌 JCOG9708; 食道癌 JCOG9708. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study …
WebA phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Abstract： OBJECTIVE:The study … greenfield superior courtWeb14 nov 2016 · The purpose of this study was to evaluate the association between tumor necrosis factor (TNF)‑α polymorphisms and oral mucositis (OM) from 5‑fluorouracil (5‑FU) plus cisplatin (CDDP) chemotherapy for esophageal cancer. The rs1799964 polymorphism of TNF‑α was genotyped using the tetra‑primer amplification refractory mutation system … flurry attack robinWeb20 gen 2024 · A phase II trial (JCOG9708) evaluating the efficacy of definitive CRT (dCRT) for stage I ESCC showed a good long-term outcome with a 4-year overall survival (OS) … flurry attack breath of the wildWebChemoradiotherapy for resectable esophageal cancer. Trial name. Stage histology. Regimen. Radiation dose (Gy). CRR (%). Survival (%). Ref.. greenfield supplyflurry attack zeldaWeb2 set 2011 · The results of JCOG9708 suggested chemoradiotherapy as a possible alternative treatment modality in stage I esophageal cancer patients. Therefore, JEOG is now conducting a phase III study (JCOG0502) to determine the non-inferiority of chemoradiotherapy compared with surgery in patients with stage I (T1b N0) ESCC. greenfields unit mount gould plymouthWeb23 giu 2009 · Methods. Patients with Stage I (T1N0M0) ESCC, aged 20-75 years, without indication of endoscopic mucosal resection were eligible. Treatment consisted of … flurry attack